X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.

Recent Posts

R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures

By Andrew Powaleny  |    December 9, 2019
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases,...   Read More

Event tomorrow: Maintaining America’s leadership in access and innovation

By Andrew Powaleny  |    October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...   Read More

Nearly 140 medicines in development to treat mental illness

By Andrew Powaleny  |    October 10, 2019
Today is World Mental Health Day, a moment where we reflect about the challenges we still face towards better treatment of mental illness and its impact on patients.   Read More

IP Explained: Understanding biopharmaceutical innovation

By Andrew Powaleny  |    July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...   Read More

Event tomorrow: Improving access and affordability for America’s seniors

By Andrew Powaleny  |    May 7, 2019
Medicare Parts B and D have played an important role in providing seniors with access to the lifesaving treatments they need and have been successful in delivering value to both the health care...   Read More

New report shows more than 160 medicines in development for diabetes and related conditions

By Andrew Powaleny  |    April 24, 2019
Diabetes represents a significant public health issue in the U.S. It affects more than 30 million Americans, including around 7.2 million who are undiagnosed. Additionally, there are close to 1.5...   Read More

New report shows nearly 20 innovative medicines in development for sickle cell disease

By Andrew Powaleny  |    April 2, 2019
Sickle cell disease (SCD) is the most common inherited blood disorder in the United States, afflicting nearly 100,000 Americans. Patients with SCD have sickle-shaped red blood cells, which have...   Read More

130 medicines in development for asthma, allergies and other respiratory diseases

By Andrew Powaleny  |    February 21, 2019
Millions of Americans suffer from respiratory diseases, including Asthma and chronic obstructive pulmonary disease (COPD). Together, these two diseases affect the day-to-day lives of over 40...   Read More

Putting 2018 medicine approvals in context

By Andrew Powaleny  |    January 23, 2019
Last year, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved a record number of novel new medicines with 59 new molecular entities (NMEs). While...   Read More

New report shows nearly 300 cell and gene therapies in development

By Andrew Powaleny  |    December 6, 2018
Fifty years ago, the idea of altering a gene to treat or even cure a disease was considered science fiction. Today, cell and gene therapy are transforming treatment options for some patients and...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates